GSK and Pfizer settle patent dispute over RSV vaccines, with GSK's product leading sales

From Yahoo Finance: 2025-04-03 18:03:00

British pharmaceutical giants GlaxoSmithKline and Pfizer have ended a lawsuit over Pfizer’s RSV vaccine Abrysvo allegedly violating GSK’s patent rights for its competing RSV shot Arexvy. Both companies agreed to dismiss the case with prejudice, with GSK’s Arexvy leading U.S. RSV vaccine sales. RSV is a respiratory disease causing cold-like symptoms and pneumonia in toddlers and older adults. Pfizer denied GSK’s allegations and argued GSK’s patents were invalid, with a separate case invalidating related UK patents owned by GSK. GSK has also sued Pfizer over patent infringement in the U.S. for Pfizer’s COVID-19 vaccine Comirnaty, with the case ongoing.



Read more at Yahoo Finance: GSK resolves patent lawsuit against Pfizer over RSV vaccines